Search results
15 lut 2022 · Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to ...
- Pfizer and OPKO’s Once-Weekly NGENLATM
NEW YORK & MIAMI--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE)...
- OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting ...
OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE)...
- Pfizer and OPKO’s Once-Weekly NGENLATM
15 gru 2014 · OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for ...
28 cze 2023 · NEW YORK & MIAMI-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to ...
28 cze 2023 · (Reuters) -The U.S. Food and Drug Administration has approved Pfizer Inc and partner OPKO Health Inc's treatment for growth hormone deficiency in children, the companies said on Wednesday.
15 lut 2022 · NEW YORK & MIAMI -- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the...
15 lut 2022 · Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency.
16 lut 2022 · Developed by pharma giant Pfizer (NYSE: PFE) and OPKO Health (Nasdaq: OPK), Ngenla is a once-weekly injection approved to treat children and adolescents from three years of age with growth disturbance due to insufficient secretion of growth hormone.
